Northwire Canada EditionTuesday, August 25, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0% GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0%
Regulatory Routine −

VVT Med Provides Update on Management Cease Trade Order

Bi-weekly regulatory update on delayed filings and ongoing MCTO restricts insider trading while commercial expansion continues.

By The Northwire Desk — AI Analysis Jun 12, 2026 · 17:00 VVTM · 0.22 VVT Med Inc.
Executive Summary
  • VVT Med Inc. issued a bi-weekly status update regarding a Management Cease Trade Order (MCTO) from the British Columbia Securities Commission (BCSC).
  • The MCTO was originally issued due to continuous disclosure defaults, specifically the delay in filing audited financial statements for the fiscal year ended December 31, 2025.
  • The company anticipates filing the overdue FYE 2025 audited financials and Q1 2026 interim financials by June 29, 2026.
  • The MCTO restricts trading by the CEO and CFO and limits corporate securities transactions with insiders until all required filings are submitted.
  • The company confirms no material changes to prior default announcements and no undisclosed material information.
Material Impact
  • The news is a routine compliance update that confirms the previously communicated June 29, 2026 filing deadline.
  • It does not introduce new commercial catalysts, financial results, or strategic shifts.
  • The MCTO remains in effect, continuing to restrict insider trading and limiting the company's ability to issue securities to insiders/employees, which constrains near-term capital flexibility.
  • Commercial activities (distribution agreements in Italy, Dominican Republic, and US) are proceeding independently, but the regulatory overhang persists without resolution.
VVTM · Price
Company Overview
  • VVT Med Inc. is a medical device company focused on the development and commercialization of the ScleroSafe system, a non-thermal, non-tumescent (NT-NT) solution for treating venous disease (varicose veins).
  • The technology enables controlled sclerosant delivery with simultaneous blood aspiration, eliminating the need for thermal energy or tumescent anesthesia.
  • The company is pursuing a global commercialization strategy through exclusive distribution partnerships, having secured agreements in India, Italy, the Dominican Republic, and the U.S. (via Northwell Health).
  • The company is listed on the TSX Venture Exchange and is in the early stages of scaling its commercial operations.
Read the original news release →

More from VVT Med Inc.

Jun 26, 2026 · 06:45

VVT Med Expands European Commercial Footprint Through Exclusive Distribution Agreement in Greece

Other Jun 11, 2026 · 08:30

Early-stage venous disease device maker scales global distribution while navigating regulatory delays and dilutive capital raises.

Financings May 29, 2026 · 17:32

VVT Med’s Italian Breakthrough Overshadowed as Cease Trade Order Drags Shares to Multi‑Year Lows

Regulatory May 26, 2026 · 08:00

Operational Milestone Achieved Amidst Regulatory Overhang

Production / Operations May 15, 2026 · 17:31

Governance Risks Persist Despite Commercial Traction

Regulatory May 01, 2026 · 19:44

VVT Med Cease Trade Order Halts Financing Flexibility Amidst Commercial Momentum

Regulatory